Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) Short-Term Debt repayments (2018 - 2025)

BioNexus Gene Lab's Short-Term Debt repayments history spans 5 years, with the latest figure at $34187.0 for Q3 2025.

  • For Q3 2025, Short-Term Debt repayments rose 117.36% year-over-year to $34187.0; the TTM value through Sep 2025 reached -$163166.0, up 17.4%, while the annual FY2019 figure was -$1061.0, 173.58% down from the prior year.
  • Short-Term Debt repayments for Q3 2025 was $34187.0 at BioNexus Gene Lab, up from -$196982.0 in the prior quarter.
  • Across five years, Short-Term Debt repayments topped out at $34187.0 in Q3 2025 and bottomed at -$196982.0 in Q3 2024.